Drug Trial Radar · NCT06082167
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jun 7, 2024
Primary completion
Aug 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- ExelixisIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.
Conditions
- Head and Neck Squamous Cell Carcinoma
Interventions
ZanzalintinibDrug
Specified doses on specified days
Zanzalintinib-matched PlaceboDrug
Specified doses on specified days
PembrolizumabBiological
Specified doses on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)Time frame: Approximately 33 months after the first subject is randomized
- Overall Survival (OS)Time frame: Approximately 50 months after the first subject is randomized
Locations
168 sites in 26 countries. Site status is shown where the registry gives one.
Exelixis Clinical Site #2
Fullerton, California
Exelixis Clinical Site #1
Orange City, Florida
Exelixis Clinical Site #163
Tampa, Florida
Exelixis Clinical Site #123
Athens, Georgia
Exelixis Clinical Site #82
Atlanta, Georgia
Exelixis Clinical Site #19
Chicago, Illinois
Exelixis Clinical Site #62
Des Moines, Iowa
Exelixis Clinical Site #100
Iowa City, Iowa
Exelixis Clinical Site #4
St Louis, Missouri
Exelixis Clinical Site #148
Lebanon, New Hampshire
Exelixis Clinical Site #158
Camden, New Jersey
Exelixis Clinical Site #3
Shirley, New York
Exelixis Clinical Site #95
Durham, North Carolina
Exelixis Clinical Site #117
Wilson, North Carolina
Exelixis Clinical Site #43
Roanoke, Virginia
Exelixis Clinical Site #91
Buenos Aires, Argentina
Exelixis Clinical Site # 47
Ciudad Autonoma de Buenos Aire, Argentina
Exelixis Clinical Site #53
Ciudad Autonoma de Buenos Aire, Argentina
Exelixis Clinical Site #93
Córdoba, Argentina
Exelixis Clinical Site #64
Córdoba, Argentina
Exelixis Clinical Site #157
Pergamino, Argentina
Exelixis Clinical Site #92
Santa Fe, Argentina
Exelixis Clinical Site #73
Rosario, Santa Fe Province, Argentina
Exelixis Clinical Site # 46
Adelaide, Australia
Exelixis Clinical Site #154
Bedford Park, Australia
Exelixis Clinical Site #137
Camperdown, Australia
Exelixis Clinical Site #39
Murdoch, Australia
Exelixis Clinical Site #57
Port Macquarie, New South Wales, Australia
Exelixis Clinical Site #156
Linz, Austria
Exelixis Clinical Site #42
Salzburg, Austria
Exelixis Clinical Site #166
Vienna, Austria
Exelixis Clinical Site #22
Brussels, Belgium
Exelixis Clinical Site #106
Charleroi, Belgium
Exelixis Clinical Site #14
Libramont, Belgium
Exelixis Clinical Site #37
Sint-Niklaas, Belgium
Exelixis Clinical Site #116
Barretos, Brazil
Exelixis Clinical Site #75
Curitiba, Brazil
Exelixis Clinical Site #101
Curitiba, Brazil
Exelixis Clinical Site #97
Porto Alegre, Brazil
Exelixis Clinical Site #102
Recife, Brazil
Showing 40 of 168 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.